Based on our previous study and experience, we believe that the developmental signalling cascade plays a vital role during the clonal evolution of drug-resistant cancer cells. We are interested in understanding the involvement of these complex signals in the process of clonal evolution. We are also establishing novel in vitro cancer cell models to understand the process of chemotherapy-induced clonal evolution in various cancer models. 

The WNT-signaling is a dynamic developmental signalling that is crucial in cancer initiation and progression. In our projects, we are studying the metastatic driving function of both B-Catenin-dependent and independent WNT Signaling regulators.

We have one of the most extensive collections of multi-drug-resistant cancer cell line clones in our lab. Some of these clones have high tumorigenic potential tested in animal models. We believe that these cells will have several applications in cancer research and drug discovery in the upcoming days. 

A major part of our research is focused on the development of novel therapeutic small molecules and peptides against WNT signalling regulators, actin modulators, and STAT3-signaling. We are also using the combination therapy approach to discover novel anti-cancer drug combinations against metastatic and drug-resistant cancers. 

We are using various natural and synthetic biocompatible scaffolds to support 3D cell growth and drug delivery.